登録して招待リンクを共有すると、動画再生報酬と紹介報酬を獲得できます。

Shanaka Anslem Perera ⚡
@shanaka86
Author of The Ascent Begins. Independent Analyst. Money, geopolitics, AI, science, and sovereignty. Trying to understand the reality a bit better.
参加 July 2009
3.6K フォロー中    306.1K ファン
On 16th July a federally regulated exchange began taking bets on whether specific cancer and Alzheimer’s drug trials will succeed. One contract at launch asked whether AR1001 would meet its primary endpoint in early Alzheimer’s disease. Kalshi runs the markets with a data firm called AppliedXL. Polymarket lists comparable contracts. Kalshi says it lists a trial only after enrolment closes, so a visible price cannot influence recruitment. It says it will require employment verification from traders in these markets, and that its existing ban on trading with material nonpublic information applies. Those are the company’s descriptions of its own pilot. Joshua Pederson, a Boston University professor whose 12 year old son is enrolled in a cancer trial, learned the markets existed and objected to the whole category. He told NPR that a trial failing means “people are going to suffer, people are going to die, people are going to have one fewer clinical option available to them.” NPR does not name his son’s trial, and no reviewed source shows it is listed anywhere. Kalshi’s defence is that equity markets have always let investors profit from failed trials, at far larger scale. That is true, and it is also the point. Owning a share prices a company. This prices one treatment. Each contract names the public document it settles against. For trial outcomes, that document is the registered primary endpoint on The same record that says whether the drug worked.
もっと見る